Meningococcal Serogroup A, B, C, W, X, and Y Serum Bactericidal Antibody Assays
Serum bactericidal antibody (SBA) assays measure functional antibody titers against Neisseria meningitidis in sera. Induction of complement-dependent SBA after vaccination with meningococcal polysaccharide or conjugate or protein based vaccines is regarded as the surrogate of protection and thus acceptable evidence of the potential efficacy of these vaccines. This chapter discusses and details SBA assay protocols for measuring the complement-mediated lysis of serogroup A, B, C, W, X, and Y meningococci by human sera, for example, following vaccination or disease.
Key wordsNeisseria meningitidis Meningococcal Serum bactericidal antibody Complement Bactericidal
- 1.Chen WH, Neuzil KM, Boyce CR et al (2018) Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. Lancet Infect Dis 18:1088–1096Google Scholar
- 2.Feavers IM, Maiden MCJ (2017) Recent progress in the prevention of serogroup B meningococcal disease. Clin Vaccine Immunol 24. https://doi.org/10.1128/CVI.00566-16. pii: e00566-16
- 6.World Health Organization (1976) Requirements for meningococcal polysaccharide vaccine. World Health Organization technical report series, no. 594. World Health Organization, GenevaGoogle Scholar
- 7.Maslanka SE, Gheesling LL, LiButti DE et al (1997) Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diag Lab Immunol 4:156–167Google Scholar
- 8.Borrow R, Aaberge IS, Santos GF et al (2005) Interlaboratory standardization of the measurement of serum bactericidal activity using human complement against meningococcal serogroup B, strain 44/76-SL before and after vaccination with the Norwegian MenBvac OMV vaccine. Clin Diag Lab Immunol 12:970–976Google Scholar